BIOMARKER:

HER-2 exon 20 insertion

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	ado-trastuzumab emtansine Sensitive: C3 – Early Trials Anticancer Drugs - 3 weeks (New C4) ado-trastuzumab emtansine Sensitive : C3 Anticancer Drugs - 3wk	ado-trastuzumab emtansine Sensitive: C3 – Early Trials Anticancer Drugs - 3 weeks ado-trastuzumab emtansine Sensitive : C3 Anticancer Drugs - 3 weeks - (New C4)
HER-2 exon 20 insertion	Solid Tumor	HER-2 exon 20 insertion	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2	pyrotinib Sensitive: C2 – Inclusion Criteria pyrotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2	poziotinib Sensitive: C2 – Inclusion Criteria poziotinib Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2	DZD9008 Sensitive: C2 – Inclusion Criteria DZD9008 Sensitive : C2
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3	dacomitinib Sensitive: C3 – Early Trials dacomitinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	rivoceranib + pyrotinib Sensitive: C3 – Early Trials rivoceranib + pyrotinib Sensitive : C3	rivoceranib + pyrotinib Sensitive: C3 – Early Trials rivoceranib + pyrotinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3	KN046 Sensitive: C3 – Early Trials KN046 Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3	ado-trastuzumab emtansine Sensitive: C3 – Early Trials ado-trastuzumab emtansine Sensitive : C3
HER-2 exon 20 insertion	HER2 Negative Breast Cancer	HER-2 exon 20 insertion	HER2 Negative Breast Cancer	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3	trastuzumab + neratinib Sensitive: C3 – Early Trials trastuzumab + neratinib Sensitive : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
HER-2 exon 20 insertion	Non Small Cell Lung Cancer	HER-2 exon 20 insertion	Non Small Cell Lung Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4	afatinib Sensitive: C4 – Case Studies afatinib Sensitive : C4
HER-2 exon 20 insertion	HER2 Positive Breast Cancer	HER-2 exon 20 insertion	HER2 Positive Breast Cancer	neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical neratinib + ado-trastuzumab emtansine Sensitive : D	neratinib + ado-trastuzumab emtansine Sensitive: D – Preclinical neratinib + ado-trastuzumab emtansine Sensitive : D
HER-2 exon 20 insertion	HER2 Positive Breast Cancer	HER-2 exon 20 insertion	HER2 Positive Breast Cancer	neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical neratinib + fam-trastuzumab deruxtecan-nxki Sensitive : D	neratinib + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical neratinib + fam-trastuzumab deruxtecan-nxki Sensitive : D
HER-2 exon 20 insertion	Lung Adenocarcinoma	HER-2 exon 20 insertion	Lung Adenocarcinoma	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D	poziotinib Sensitive: D – Preclinical poziotinib Sensitive : D